Israel approves generic HIV drug to treat COVID-19 despite doubts [Reuters]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Reuters
Israel approves generic HIV drug to treat COVID-19 despite doubts TEL AVIV/CHICAGO (Reuters) - Israel approved the licensing of a generic version of an HIV drug to treat patients infected with the coronavirus on Thursday, despite doubts about its effectiveness in trials. The anti-viral drug Kaletra, produced by AbbVie Inc, could be a possible treatment for COVID-19, Israel’s Health Ministry said after issuing a preliminary permit. While AbbVie’s patent for Kaletra in Israel ends in 2024, the patent in some other countries, such as India, has expired. It was the first time the country’s attorney general has allowed the use of a generic version of a patent-protected drug in Israel, where there are 529 confirmed coronavirus cases. “The company with the patent and the official importer in Israel are not able to supply the necessary inventory for this drug, which is very much in demand all over the world these days,” the Justice Ministry said in a statement. “Therefore ... the state will b
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- Health officials warn Californians of risks of fake Botox. Here's what to look for [Los Angeles Times (CA)]Los Angeles Times
- California health officials: Fake Botox injections causing hospitalizations, adverse reactions [CBS News]CBS News
- QULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults [Yahoo! Finance]Yahoo! Finance
- BeiGene Reports First Quarter 2024 Financial Results and Business Updates [Yahoo! Finance]Yahoo! Finance
- Information Mediary Corp. and Adherence Partner to Launch Revolutionary Digital MMAS Integration for Medication Adherence [Yahoo! Finance]Yahoo! Finance
ABBV
Earnings
- 4/26/24 - Miss
ABBV
Sec Filings
- 5/8/24 - Form 8-K/A
- 5/7/24 - Form 4
- 5/7/24 - Form 4
- ABBV's page on the SEC website